AU2020347539A1 - Compositions for the treatment of solid tumors - Google Patents

Compositions for the treatment of solid tumors Download PDF

Info

Publication number
AU2020347539A1
AU2020347539A1 AU2020347539A AU2020347539A AU2020347539A1 AU 2020347539 A1 AU2020347539 A1 AU 2020347539A1 AU 2020347539 A AU2020347539 A AU 2020347539A AU 2020347539 A AU2020347539 A AU 2020347539A AU 2020347539 A1 AU2020347539 A1 AU 2020347539A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
weight
formula
composition comprises
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020347539A
Other languages
English (en)
Inventor
Eran Blaugrund
Alon BLOOMENFELD
Racheli GUETA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raziel Therapeutics Ltd
Original Assignee
Raziel Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raziel Therapeutics Ltd filed Critical Raziel Therapeutics Ltd
Publication of AU2020347539A1 publication Critical patent/AU2020347539A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020347539A 2019-09-15 2020-09-14 Compositions for the treatment of solid tumors Pending AU2020347539A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900557P 2019-09-15 2019-09-15
US62/900,557 2019-09-15
PCT/IB2020/000745 WO2021048626A1 (en) 2019-09-15 2020-09-14 Compositions for the treatment of solid tumors

Publications (1)

Publication Number Publication Date
AU2020347539A1 true AU2020347539A1 (en) 2022-03-31

Family

ID=74866186

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020347539A Pending AU2020347539A1 (en) 2019-09-15 2020-09-14 Compositions for the treatment of solid tumors

Country Status (7)

Country Link
US (1) US20220323411A1 (https=)
EP (1) EP4031130A4 (https=)
JP (1) JP7822308B2 (https=)
CN (1) CN115066241A (https=)
AU (1) AU2020347539A1 (https=)
IL (1) IL291351A (https=)
WO (1) WO2021048626A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307323B1 (en) 2015-06-15 2022-07-13 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
EP4334286A4 (en) * 2021-05-06 2025-03-19 Raziel Therapeutics Ltd. CRYSTALLINE CARBAZOLE DERIVATIVE
CN120693158A (zh) * 2022-11-07 2025-09-23 拉结尔治疗有限公司 结晶咔唑衍生物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
UA107652C2 (en) 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
KR101986272B1 (ko) * 2011-11-15 2019-06-05 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
EP3307323B1 (en) * 2015-06-15 2022-07-13 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
US20230089484A1 (en) 2020-01-28 2023-03-23 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma

Also Published As

Publication number Publication date
EP4031130A1 (en) 2022-07-27
CN115066241A (zh) 2022-09-16
JP2023503769A (ja) 2023-02-01
IL291351A (en) 2022-05-01
EP4031130A4 (en) 2023-10-11
WO2021048626A1 (en) 2021-03-18
US20220323411A1 (en) 2022-10-13
JP7822308B2 (ja) 2026-03-02

Similar Documents

Publication Publication Date Title
JP7822308B2 (ja) 固形腫瘍の処置のための組成物
US20090325906A1 (en) Methods and compositions for therapeutic treatment
KR20100051829A (ko) 인산화된 피론 유사체 및 방법
CN115335047B (zh) 用于治疗血管脂肪瘤的组合物
US20220387434A1 (en) Combination of a btk inhibitor and an mdm2 inhibitor for cancer treatment
US20170224688A1 (en) Methods of Using BTK Inhibitors to Treat Dermatoses
US12264152B2 (en) Certain chemical compositions and methods of use thereof
US20230355584A1 (en) Compositions and methods for the treatment of lipid-related disorders
WO2022058792A1 (en) Compositions for the treatment of fat related conditions and disorders
US20240335424A1 (en) Compositions and methods for treating lipoma pain
HK40077772A (en) Compositions for the treatment of solid tumors
US20230159569A1 (en) Dual hdac6/proteasome inhibitors, and methods of use thereof
WO2025231380A1 (en) Proteolysis targeting chimeras and methods of use thereof